Materials and Methods

Bacterial Strains and Growth Conditions
Lactococci were grown in M17 broth (Oxiod, Hampshire, UK) supplemented with 0.4% (w/v) glucose (GM17), Lactobacilli and Pediococci were grown in deMan, Rogosa and Sharpe (MRS) (Oxoid, Hampshire, UK) medium at 30 °C. E. coli, Pseudomonas aeruginosa, and Acinetobacter strains were grown in Lysogeny broth (Oxoid, Hampshire, UK) or Mueller Hinton Broth (MHB) (BD Difco, MD, USA) at 37 °C with shaking at 225 rpm. Other strains were grown in Brain Heart Infusion (Oxoid, Hampshire, UK) broth at 30 °C.
Antimicrobial Agents
Nisin from Lactococcus lactis (2.5% purity), polymyxin B sulfate and farnesol were from Sigma-Aldrich, Co. (St. Louis, MO, USA). Crude garvicin KS was prepared by following procedure. 1 L of GM17 broth was inoculated with 1% of an overnight culture of L. garvieae KS1546 and incubated at 30 °C for 8 h. The cells were removed by centrifugation at 12,000×g for 25 min and 258 g of ammonium sulfate was dissolved in the cell-free supernatant, and the mixture was left at 4 °C for 24 h. The crude bacteriocin was precipitated by centrifugation at 15,000×g for 30 min at 4 °C, dissolved in 20 mL water and kept in a boiling water bath for 10 min.
Inhibition and Checkerboard Assays
Growth inhibition was determined in microtiter plates with 200 µL of growth medium in each well as described by Holo et al. [16] . The minimum inhibitory concentration (MIC 50 ) refers to the concentration of antimicrobial agent causing 50% growth inhibition, the MIC 50 was detected once the OD 600 of testing strains reaches 0.4-0.5. Bacteriocin unit [2] of garvicin KS was defined as the amount of garvicin KS causing 50% growth inhibition of L. lactis IL1403 in this assay. The checkerboard assays using mixture of antimicrobials were performed in microtiter plates as described above.
Interactions between antimicrobial agents were determined by using the fractional inhibition concentration (FIC). The FIC was calculated as follows: FIC = FICa + FICb + FICc, where the FICa means MIC of A in combination/MIC of A alone, FICb means MIC of B in combination/MIC of B, and FICc means MIC of C in combination/MIC of C alone. Effects were considered as synergistic if FIC was ≤0.5 for two components mixture [22] and ≤0.75 for three components mixture [3] .
Time-Kill Assays
Time-kill assays were performed using cultures grown overnight and then diluted 100× in MHB with different concentrations of antimicrobial agents. The assays were done in triplicate. Total viable count (TVC) was determined by plating on Mueller Hinton agar. The agar plates were incubated at 37 °C, and the TVC was estimated after 24 h incubation. Interactions between antimicrobial agents were interpreted as synergistic when they in mixture caused ≥2-log decrease in TVC compared to the antimicrobial agents alone [25] .
Results
Garvicin KS has a Broad Antimicrobial Inhibition Spectrum
Garvicin KS, produced by L. garvieae strain, is composed of three similar peptides [24] . Initially, its inhibitory activity was tested using an agar diffusion assay [24] on 250 indicator strains, of which 240 strains (19 species) were Gram-positive. All the Gram-positive bacteria tested, with the exception of three out of 53 S. aureus strains, were sensitive (results not shown) tested. The MICs of garvicin KS against a representative selection of the strains are shown in Table 1 . Garvicin KS inhibited pathogens like Listeria monocytogenes, S. aureus, and vegetative cells of Bacillus cereus. The effect of garvicin KS on spores were not tested. The most sensitive bacteria were strains of the lactic acid bacteria Lactococcus and Enterococcus, with MIC ranging from 5 to 80 BU/mL. 5 BU/mL corresponds to a mixture of 10 nM of each of the pure peptides of garvicin KS [24] . Concentrations to inhibit other Gram-positive strains varied from 320 to 2560 BU/mL. Notably, garvicin KS was inhibitory to A. baumannii, A. iwoffii, and A. calcoaceticus (MIC = 2560 BU/mL). However, other Gram-negative bacteria, such as E. coli and P. aeruginosa, did not show any sensitivity to garvicin KS in this assay.
Garvicin KS Acts Synergistically with Other Antimicrobials Against S. aureus
Staphylococcus aureus LMGT 3242 was the least sensitive Gram-positive bacterium tested in the microtiter assay, and in time-kill assays we were unable to fully prevent growth of this bacterium even with high concentration of garvicin KS. We therefore used this strain to investigate the effects of combining garvicin KS with other antimicrobials, including nisin, another bacteriocin with a wide inhibitory spectrum [1] and farnesol, shown to act as adjuvant to antimicrobials in Staphylococci [17] . Using the checkerboard assay, we found synergy between nisin and garvicin KS (FIC = 0.22) and between bacteriocins and farnesol, (both with FICs of 0.47), and all three compounds in combination (FIC = 0.33) ( Table 2 ). The three components mixture resulted in the reduction of MIC by a factor of 8 for farnesol, and by a factor of 10 for garvicin KS and nisin, respectively.
The effects of garvicin KS, nisin, and farnesol to S. aureus were also studied in time-kill assay. In the experiments, concentrations corresponding to the MIC (Table 2) were used. As shown in Fig. 1 , none of the three antimicrobials alone could completely kill the bacteria even after 48 h exposure. When tested alone nisin and garvicin KS both caused an initial 3-log reduction in TVC before growth of survivors was detected. The mixtures nisin + garvicin KS caused a complete killing after about 12 h and no regrowth was seen even after 48 h, demonstrating the strong synergy between the two bacteriocins. Killing using the farnesol + garvicin KS mixture was less efficient, causing 4, 5 log reduction of CFU before the growth started. The farnesol + nisin mixture, on the other hand, gave complete killing after 12 h, as did the combination of all three compounds. We tested six other strains of S. aureus, including three MRSA, in the time-kill assay using the same concentrations as shown in Fig. 1 . All strains were sensitive to nisin and garvicin KS, but none were eradicated by these bacteriocins alone or in combination. Only one of the six strains was completely killed by the mixture of nisin and farnesol. However, the mixture of farnesol, nisin, and garvicin KS caused complete killing of all six strains.
Antimicrobial Synergy Against Gram-Negative Bacteria
A unique feature of garvicin KS is that it has antimicrobial effects on Acinetobacter spp., but relatively high amount of garvicin KS was required to inhibit them. Recently, farnesol was found to be a good adjuvant with polymyxin B to A. baumannii [18] , and like for S. aureus; we tested farnesol in mixture with garvicin KS for synergy in inhibiting Acinetobacter spp.. No synergy was seen with these combinations (data not shown). We therefore replaced farnesol with polymyxin B in the mixtures.
The A. baumannii and A. calcoaceticus strains tested were both sensitive to polymyxin B with a MIC of 0.63 µg/ mL, while A. iwoffii with a MIC of 25 µg/mL is considered resistant [2] (Table 3) . Synergy was seen between polymyxin B and garvicin KS against all three Acinetobacter strains tested, even the polymyxin B resistant A. iwoffii. Similar synergistic effects were seen between nisin and polymyxin B. The combinations of three antimicrobial agents also showed synergistic effects against all the Acinetobacter strains. Compared to the individual antimicrobials combining the three compounds caused about 10-fold and 15-fold MIC reductions for garvicin KS and polymyxin B, respectively (Table 3) .
The effects on A. baumannii of nisin, garvicin KS, polymyxin B alone and in mixtures were assayed in time-kill assays using concentrations corresponding to the MIC values shown in Table 3 . As shown in Fig. 2 , garvicin KS and polymyxin B could both kill the bacteria, but regrowth was seen after about 8 h and an initial 2-3 log killing in either case. Mixing garvicin KS and polymyxin B prevented regrowth of the bacteria, but the nisin + polymyxin B mixture did not. The bacteria were rapidly killed by the mixture of the three components, reaching eradication after 4 h. Prompted by the results using Acinetobacter strains, we extended the synergy studies to other Gram-negative bacteria. Garvicin KS and nisin were unable to kill E. coli alone, but the strain tested was sensitive to polymyxin B (MIC = 0.3 µg/mL). Both bacteriocins showed synergy with polymyxin B. A FIC of 0.4 was found for two-and three components mixture with polymyxin B (Table 3 ). The synergies were also demonstrated in time-kill assays (Fig. 3) . Both bacteriocins improved the killing rates compared to polymyxin B alone, but regrowth was seen. The mixture of all three components, however, caused eradication of the bacteria after 8 h exposure.
We also tested synergy effects by using garvicin KS, nisin, and polymyxin B against P. aeruginosa. The MIC for polymyxin B against the strain tested was 0.8 µg/mL. However, there were no synergy effects on their combinations (data not shown).
Discussion
Garvicin KS is a new bacteriocin comprised of three similar peptides of 32-34 amino acids [24] . The bacteriocin shows a broad inhibitory spectrum encompassing all the Grampositive genera tested. Such a wide spectrum of activity is uncommon among bacteriocins, and has only been reported for certain lantibiotics like nisin and lactacin 3147 [11] . Of note, unlike the lantibiotics, garvicin KS was able to inhibit Gram-negative bacteria of Acinetobacter genus. However, the sensitivity towards garvicin KS varied more than 500-fold between the bacteria tested. Relatively high amounts of garvicin KS were required to kill many of the pathogenic species tested, and these bacteria were not completely killed and regrew after initial killing.
Combining antimicrobial agents offers a potential for increasing antimicrobial treatment efficacy and for reducing resistance evolution, and the use of combination antimicrobial therapy is widely used in the treatment of serious infections [4] . Importantly, the individual bacteriocins may act more effectively in combination with other antimicrobials agents [6] , and studies demonstrating such effects have recently been reviewed [19] . Here, we have shown that garvicin KS is synergistic with other antimicrobial compounds, improving killing kinetics, and eradication and hence reducing resistance development. It is notable that garvicin KS could act synergistically with all the three compounds tested, indicating differences in mode of killing. Importantly, garvicin KS showed synergy with polymyxin B, a drug of last resort in the combat infections by multidrug resistant Gram-negative bacteria but which is avoided due to its toxicity at relevant concentrations [9, 26] . Moreover, the emergence of resistance to polymyxins has been reported [8, 10] . Synergy between polymyxins and nisin and lacticin 3147, both bacteriocins from Gram-positive bacteria, against Gram-negative bacteria has been reported [13, 20, 21] . The synergy can be attributed to disruption of the outer membrane by polymyxin B allowing access of the bacteriocins to their target [7] . Polymyxin B is used for treatment of nosocomial infections mostly caused by A. baumannii, but because surviving bacteria are frequently found most patients are recommended to receive combination therapy of polymyxin B with other agents active against A. baumannii [23, 29] . The potential benefits of combining with new bacteriocins, like garvicin KS that act synergistically are obvious. Importantly, the concentration of polymyxin B needed to eradicate the bacteria was significantly reduced in combination with garvicin KS and nisin and much lower than the dosage recommended for polymyxin B therapy [29] .
Strong synergy between nisin and garvicin KS was also observed against S. aureus. The synergy indicates that garvicin KS and nisin have different modes of action, which is different from classical antibiotics. Importantly, against S. aureus they were both synergistic with farnesol, a cheap and harmless compound which has been considered a promising adjuvant for antibiotics [15] . Moreover, the mixture of farnesol, nisin and garvicin KS completely killed all the S. aureus tested.
In conclusion, garvicin KS is a promising antimicrobial agent. We have demonstrated activity against a wide variety of bacteria, including pathogenic species known to account for a large number nosocomial infections, often with multi-resistant strains. The mode of action of garvicin KS is unknown, but different from many other used antimicrobials. Furthermore, garvicin KS mixtures with other antimicrobial compounds can be highly efficient by improving killing kinetics and eradication hence lower resistance development.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Control Polymyxin B (0.3 μg/mL) Garvicin KS (3200 BU/mL) Nisin (10 μg/mL) Polymyxin B (0.12 μg/mL) + Nisin (10 μg/mL) Garvicin KS (3200 BU/mL) + Polymyxin B (0.12 μg/mL) Garvicin KS (3200 BU/mL) + Nisin (10 μg/mL) Garvicin KS (3200 BU/mL) + Polymyxin B (0.12 μg/mL) + Nisin (4 μg/mL) Fig. 3 Time-killing analysis reveals the antimicrobial effects of garvicin KS, nisin, and polymyxin B against E. coli LMGT 3704. Viable counts were determined in triplicate
